The Lancet Diabetes & Endocrinology, dedicated to covering the disciplines of diabetes, endocrinology, and metabolism, is the latest title in The Lancet family of specialty journals. Continuing in ...

An FDA-approved medication already used to treat people who have type 2 diabetes and chronic kidney disease may also help ...

Lancets play an integral part in glucose monitoring for diabetes management as single-use designs help ensure safety and hygiene thereby decreasing risks of infections or cross-contamination ...

Sotagliflozin, recently approved by the FDA for treating type 2 diabetes and kidney disease in patients with cardiovascular ...

Sotagliflozin significantly reduces heart attacks and strokes in high-risk patients with diabetes and kidney disease, offering a new treatment option for cardiovascular protection. Sotagliflozin, a re ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

While conducting the study, the researchers tracked data from more than 10,000 patients who presented with type 2 diabetes, ...

A newly approved drug for type 2 diabetes and kidney disease, sotagliflozin, has shown remarkable benefits in reducing the ...

The prevalence of diabetes is increasing faster in some low-income countries than elsewhere in the world, generating concerns ...

Sotagliflozin belongs to a class of medications called gliflozins that help lower blood sugar levels by preventing the ...

About a quarter of the 828 million adults globally living with diabetes — either type 1 or 2 — are in India, a paper published in The Lancet said on Wednesday. Apart from the 212 million ...